Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-17 of 17

Sort by

Sort Order Select

Journal Articles

BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor

Blood (2024) 143 (20): 2059–2072.

https://doi.org/10.1182/blood.2023022832

Published: 2024

Includes: Supplemental data

Journal Articles

Novel Agents with Efficacy Against Cellular Models of Familial Platelet Disorder with Myeloid Malignancy (FPD-MM) Associated with Germline Mutant RUNX1

Christopher Peter Mill, Warren C. Fiskus, Courtney D. DiNardo, Patrick K Reville, John Davis, Christine Birdwell, Kaberi Das, Hanxi Hou, Koichi Takahashi, Sanam Loghavi, Joseph D. Khoury, Kapil N. Bhalla

Blood (2023) 142 (Supplement 1): 2765.

https://doi.org/10.1182/blood-2023-190655

Published: 2023

Journal Articles

IFNγ Signaling in Acute Myeloid Leukemia Mediates Immunomodulation and Reveals Therapeutic Strategies

Blood (2023) 142 (Supplement 1): 2796.

https://doi.org/10.1182/blood-2023-175010

Published: 2023

Journal Articles

Outcomes of Patients (pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) and TP53 mutation/Loss Treated on the Phase 2 Study of Venetoclax (Ven) Added to Alternating Cladribine (Clad) Plus Low-Dose Cytarabine (LDAC) and Azacitidine (Aza): A Subgroup Analysis

Jayastu Senapati, Sanam Loghavi, Patrick K Reville, Naval Daver, Gautam Borthakur, Courtney D. DiNardo, Elias Jabbour, Nicholas J. Short, Naveen Pemmaraju, Abhishek Maiti, Ghayas C. Issa, Uday R. Popat, Amin Alousi, Elizabeth J. Shpall, Koji Sasaki, Guillermo Garcia-Manero, Farhad Ravandi, Tapan M. Kadia

Blood (2023) 142 (Supplement 1): 4282.

https://doi.org/10.1182/blood-2023-179380

Published: 2023

Journal Articles

Prospective Pharmacokinetic Evaluation of Venetoclax (VEN) in AML Demonstrates Significant and Variable Drug Interactions with Azole Antifungals That Increase Ven Exposure, Reduce Clearance, and Necessitate Re-Evaluation of Dose Adjustments

Jitesh Kawedia, Caitlin R Rausch, Xiaoqian Li, Courtney D. DiNardo, Farhad Ravandi, Naval Daver, Gautam Borthakur, Naveen Pemmaraju, Patrick K Reville, Nicholas J. Short, Elias Jabbour, Guillermo Garcia-Manero, Hagop M. Kantarjian, Tapan M. Kadia

Blood (2023) 142 (Supplement 1): 2885.

https://doi.org/10.1182/blood-2023-180491

Published: 2023

Journal Articles

Single-Cell Polyfunctional Proteomic Profiling Reveals Temporal and Niche Differences in CD4 and CD8 T Cells in Acute Myeloid Leukemia Following PD-1 Blockade Therapy

Jessica Lynn Root, Poonam N Desai, Patrick K Reville, Christopher Ly, Bofei Wang, Fatima Z Jelloul, Jing Zhou, Sean Gregory Mackay, Mansour Alfayez, Jairo Matthews, Sherry Pierce, Naval Daver, Hussein A Abbas

Blood (2023) 142 (Supplement 1): 1584.

https://doi.org/10.1182/blood-2023-188268

Published: 2023

Journal Articles

Patterns of Relapse in Patients with Acute Myeloid Leukemia (AML) Treated with Venetoclax-Containing Regimens

Naszrin Arani, Emmanuel Almanza, Alex Bataller, Courtney D. DiNardo, Farhad Ravandi, Naval Daver, Naveen Pemmaraju, Musa Yilmaz, Abhishek Maiti, Patrick K Reville, Sanam Loghavi, Hussein A Abbas, Guillermo Garcia-Manero, Nicholas J. Short, Hagop M. Kantarjian, Tapan M. Kadia

Blood (2023) 142 (Supplement 1): 4236.

https://doi.org/10.1182/blood-2023-191181

Published: 2023

Journal Articles

Single-Cell Characterization of TP53-Mutated AML Patients Treated with Frontline Azacitidine, Venetoclax, and Magrolimab Reveals Mechanisms of Response and Resistance

Poonam N Desai, Bofei Wang, Patrick K Reville, Fatima Z Jelloul, Pamella Borges, Jayastu Senapati, Micah Castillo, Preethi Gunaratne, Naveen Pemmaraju, Tapan M. Kadia, Farhad Ravandi, Guillermo Garcia-Manero, Naval Daver, Hussein A Abbas

Blood (2023) 142 (Supplement 1): 64.

https://doi.org/10.1182/blood-2023-187307

Published: 2023

Journal Articles

Characterizing Inferred Functional and Phenotypical States of Newly Diagnosed Acute Myeloid Leukemia from Single Cell Transcriptomic Profiling

Bofei Wang, Christopher Ly, Enes Dasdemir, Fatima Z Jelloul, Poonam N Desai, Pamella Borges, Jessica Lynn Root, Guilin Tang, Preethi Gunaratne, Sreyashi Basu, Sonali Jindal, Yulong Chen, Khalida M Wani, Alexander J Lazar, Padmanee Sharma, Patrick K Reville, Hussein A Abbas

Blood (2023) 142 (Supplement 1): 2938.

https://doi.org/10.1182/blood-2023-178345

Published: 2023

Journal Articles

The Adverse Effect of Myelodysplasia-Related Mutations in De Novo Acute Myeloid Leukemia Is Associated with Higher Variant Allelic Frequency (VAF): A Proposal for a Numeric Cutoff for Variant Allelic Frequency

Blood (2022) 140 (Supplement 1): 6306–6308.

https://doi.org/10.1182/blood-2022-164494

Published: 2022

Journal Articles

Venetoclax Added to Cladribine (CLAD) + Low Dose AraC (LDAC) Alternating with Azacitidine (AZA) Is Highly Active As Frontline Therapy in Older Patients with Newly Diagnosed Acute Myeloid Leukemia in a Phase 2 Study

Blood (2022) 140 (Supplement 1): 9041–9043.

https://doi.org/10.1182/blood-2022-168029

Published: 2022

Journal Articles

Venetoclax Combined with Cladribine, Idarubicin, Cytarabine (CLIA) As Induction Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

Blood (2022) 140 (Supplement 1): 1702–1704.

https://doi.org/10.1182/blood-2022-167931

Published: 2022

Journal Articles

Phase II Study of Venetoclax Added to Cladribine (CLAD) and Low Dose AraC (LDAC) Alternating with 5-Azacytidine (AZA) in Older and Unfit Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Blood (2021) 138 (Supplement 1): 367.

https://doi.org/10.1182/blood-2021-147360

Published: 2021

Journal Articles

Predictors of Early Mortality, Response, and Survival in Newly Diagnosed Acute Myeloid Leukemia (AML) Using a Contemporary Academic Cohort

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-141837

Published: 2020

Journal Articles

Cladribine, Idarubicin, Cytarabine (ara-C), and Venetoclax in Treating Patients with Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

Blood (2020) 136 (Supplement 1): 7–9.

https://doi.org/10.1182/blood-2020-141075

Published: 2020

Journal Articles

Clinical Course, Outcomes and Genetic Characterization of Patients with Isolated Myeloid Sarcoma

Hussein A Abbas, MDPhD, Patrick K Reville, MD, Alexis Geppner, Maro Ohanian, DO, Koji Sasaki, MD, Gautam Borthakur, MD, Naval Daver, MD, Courtney D. DiNardo, MD MSCE, Carlos E. Bueso-Ramos, MD PhD, Michael Andreeff, MD PhD, Nicholas J. Short, MD, Sherry A. Pierce, BSN, BA, Elias Jabbour, MD, Guillermo Garcia-Manero, MD, Marina Konopleva, MD PhD, Farhad Ravandi, MBBS, Hagop M. Kantarjian, MD, Tapan M. Kadia, MD

Blood (2020) 136 (Supplement 1): 25–26.

https://doi.org/10.1182/blood-2020-138459

Published: 2020

Journal Articles

Single-Cell Characterization of Acute Myeloid Leukemia (AML) and Its Microenvironment Identifies Signatures of Resistance to PD-1 Blockade Based Therapy

Blood (2020) 136 (Supplement 1): 29–31.

https://doi.org/10.1182/blood-2020-137335

Published: 2020

NARROW

BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor

Novel Agents with Efficacy Against Cellular Models of Familial Platelet Disorder with Myeloid Malignancy (FPD-MM) Associated with Germline Mutant RUNX1

IFNγ Signaling in Acute Myeloid Leukemia Mediates Immunomodulation and Reveals Therapeutic Strategies

Outcomes of Patients (pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) and TP53 mutation/Loss Treated on the Phase 2 Study of Venetoclax (Ven) Added to Alternating Cladribine (Clad) Plus Low-Dose Cytarabine (LDAC) and Azacitidine (Aza): A Subgroup Analysis

Prospective Pharmacokinetic Evaluation of Venetoclax (VEN) in AML Demonstrates Significant and Variable Drug Interactions with Azole Antifungals That Increase Ven Exposure, Reduce Clearance, and Necessitate Re-Evaluation of Dose Adjustments

Single-Cell Polyfunctional Proteomic Profiling Reveals Temporal and Niche Differences in CD4 and CD8 T Cells in Acute Myeloid Leukemia Following PD-1 Blockade Therapy

Patterns of Relapse in Patients with Acute Myeloid Leukemia (AML) Treated with Venetoclax-Containing Regimens

Single-Cell Characterization of TP53-Mutated AML Patients Treated with Frontline Azacitidine, Venetoclax, and Magrolimab Reveals Mechanisms of Response and Resistance

Characterizing Inferred Functional and Phenotypical States of Newly Diagnosed Acute Myeloid Leukemia from Single Cell Transcriptomic Profiling

The Adverse Effect of Myelodysplasia-Related Mutations in De Novo Acute Myeloid Leukemia Is Associated with Higher Variant Allelic Frequency (VAF): A Proposal for a Numeric Cutoff for Variant Allelic Frequency

Venetoclax Added to Cladribine (CLAD) + Low Dose AraC (LDAC) Alternating with Azacitidine (AZA) Is Highly Active As Frontline Therapy in Older Patients with Newly Diagnosed Acute Myeloid Leukemia in a Phase 2 Study

Venetoclax Combined with Cladribine, Idarubicin, Cytarabine (CLIA) As Induction Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

Phase II Study of Venetoclax Added to Cladribine (CLAD) and Low Dose AraC (LDAC) Alternating with 5-Azacytidine (AZA) in Older and Unfit Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Predictors of Early Mortality, Response, and Survival in Newly Diagnosed Acute Myeloid Leukemia (AML) Using a Contemporary Academic Cohort

Cladribine, Idarubicin, Cytarabine (ara-C), and Venetoclax in Treating Patients with Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

Clinical Course, Outcomes and Genetic Characterization of Patients with Isolated Myeloid Sarcoma

Single-Cell Characterization of Acute Myeloid Leukemia (AML) and Its Microenvironment Identifies Signatures of Resistance to PD-1 Blockade Based Therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only